产品介绍
| miRNA抑制剂可以特异、高效地抑制生物体内源性miRNA的活性,是研究miRNA功能缺失的重要工具。GeneCopoeia提供慢病毒或非病毒载体的miArrest™ miRNA抑制剂表达克隆和化学合成的miRNA抑制剂。 | |
| miArrest™ miRNA抑制剂克隆可以特异性地结合目的miRNA,瞬时和稳定地抑制miRNA的功能,采用H1或者U6启动子驱动转录可以保证在大多数哺乳动物细胞中高水平表达。 |
优势
覆盖面广
- 针对所有已知的人、小鼠和大鼠miRNA
灵活的载体选择
- 慢病毒载体可转导普通细胞和难转染、未分化细胞
- 非病毒载体可进行稳定或瞬时转导
先进可靠的设计
- 表达框经过专利算法设计并经过严格的实验验证
抑制性能优越
- 与其他化学合成的miRNA抑制剂相比具有更强、更持久的抑制作用和极低的细胞毒性(参照表1)
- 采用H1或U6启动子保证在大多数哺乳动物细胞中高水平表达
高通量兼容
- 快速简便的实验设计
- 可同时检测多个样
HEK293细胞中共转染miR-125a 抑制剂表达质粒 (GeneCopoeia HmiR-AN0094-AM01) 、miR-125a 前体表达质粒(GeneCopoeia HmiR0309-MR03) 和miR-125a的靶标克隆质粒(GeneCopoeia HmiT019205-MT02:将LIN28 的3’UTR克隆到Gaussia荧光素酶-碱性磷酸酶双报告载体)。转染24小时后检测报告基因Gaussia 荧光素酶和参照基因碱性磷酸酶的活性。只转染Gluc-LIN28-3’-UTR质粒的细胞中Gaussia 荧光素酶与碱性磷酸酶活性比值设为1 (左数第一条柱),用来标准化其他细胞样品中的报告基因活性。结果表明miR-125a抑制了Gluc-LIN28-3’-UTR中Gluc 70%以上的活性(左数第二条柱)。这种抑制效应可被导入的不同剂量的miR-125a抑制剂表达质粒特异性的阻遏。转染100 ng 抑制剂表达质粒时,细胞内报告基因/参照基因活性比值(右数第一条)已超出单独转染Gluc-LIN28-3’-UTR报告质粒的对照组。这说明miR-125a抑制剂可以阻遏外源和内源性的miR-125a对靶标基因的抑制,提高GLuc-LIN28-3’-UTR转录本的翻译水平。
| 基于克隆载体的抑制剂 | 2′-甲氧修饰的抑制剂 | 化学合成的LNA抑制剂 | |
| 抑制效力 | +++++ | ++ | ++ |
| 特异性 | +++++ | +++ | +++ |
| 稳定性 | +++++ | + | +++ |
| 持久性 | Long term | Transient | Transient |
| 细胞毒性 | – | – | + |
| 导入细胞难易程度 | +++++ | – | – |
表1. 基于克隆表达载体的和化学合成的miRNA抑制剂的比较
图2. miRNA抑制剂表达克隆的作用机理
|
miRNA 抑制剂克隆导入细胞后表达的miRNA抑制剂(miArrest)特异地结合它们的靶miRNA。miRNA抑制剂转录后折叠形成一个稳定的陷阱结构,可以结合两分子靶miRNA。 miArrest™高效、特异地结合细胞内成熟的靶miRNA,阻止了miRNA对靶标mRNA的降解或者翻译抑制,上调miRNA靶标基因的表达。 独特的载体设计确保最大的特异性、抑制强度、抑制作用持久度和最低的脱靶效应。 |
载体
miRNA抑制剂表达克隆载体
| 载体 | 报告基因 | 筛选标记 | 启动子 | 载体类型 |
|---|---|---|---|---|
| pEZX-AM01 | mCherry | Puromycin | H1 | Mammalian |
| pEZX-AM02 | mCherry | Puromycin | U6 | Mammalian |
| pEZX-AM03 | mCherry | Hygromycin | H1 | HIV Lentiviral |
| pEZX-AM04 | mCherry | Hygromycin | U6 | HIV Lentiviral |
| pEZX-AM04p | mCherry | Puromycin | U6 | HIV Lentiviral |
miRNA抑制剂表达AAV载体
| 载体 | 报告基因 | 筛选标记 | 启动子 | 载体类型 |
|---|---|---|---|---|
| pEZX-AM06 | mCherry | Hygromycin | H1 | AAV |
| pEZX-AM07 | mCherry | Hygromycin | U6 | AAV |
慢病毒载体的miRNA抑制剂表达克隆 |
GeneCopoeia提供客户定制的慢病毒载体miRNA抑制剂表达克隆,周期2-5周。
化学合成的miRNA抑制剂
需要优化设计的miRNA抑制剂,点击了解更多
| 产品 | 规格 |
|---|---|
| Synthetic miRNA mimics | 5 nmol |
| Synthetic miRNA controls | 1.25 nmol |
| Synthetic miRNA inhibitors | 10 nmol |
| Synthetic miRNA inhibitor controls | 2.5 noml |
克隆套装
miRNA抑制剂表达克隆套装
GeneCopoeia除了提供单个克隆,也提供预制和定制的miRNA抑制剂表达克隆套装。了解详情请点击联系我们或拨打400-6020-200。
| 载体 | 载体类型 | 启动子 | 筛选标记 | Tag |
|---|---|---|---|---|
| pEZX-AM03 | Mammalian expression (lentiviral) | H1 | Hygromycin | mCherry |
如果您有什么问题,请致电4006-020-200,或发邮件至sales@igenebio.com。
| 载体: | 套装类型 : |
| 货号 | 旧货号 | 物种 | 套装类型 | 产品 | 相关疾病 | miRNA | 载体 | 价格 |
|---|---|---|---|---|---|---|---|---|
| MIC-AF001-AM03 | MIC-HG-AM03 | Human | Whole genome | Human whole genome miRNA inhibitor Clone set (lentiviral) | 1111 | pEZX-AM03 |
Inquire | |
| MIC-AF004-AM03 | MIC-HCA-AM03 | Human | Cancer | Human pituitary adenoma miRNA inhibitor Clone set (Lentiviral) | Pituitary Adenoma | 33 | pEZX-AM03 |
Inquire |
| MIC-AF005-AM03 | MIC-HCB-AM03 | Human | Cancer | Human breast cancer miRNA inhibitor Clone set (Lentiviral) | Breast cancer | 158 | pEZX-AM03 |
Inquire |
| MIC-AF006-AM03 | MIC-HCC-AM03 | Human | Cancer | Human colorectal cancer miRNA inhibitor Clone set (Lentiviral) | Colorectal cancer | 175 | pEZX-AM03 |
Inquire |
| MIC-AF007-AM03 | MIC-HCE-AM03 | Human | Cancer | Human mesothelioma miRNA inhibitor Clone set (Lentiviral) | Mesothelioma | 21 | pEZX-AM03 |
Inquire |
| MIC-AF008-AM03 | MIC-HCG-AM03 | Human | Cancer | Human gastric cancer miRNA inhibitor Clone set (Lentiviral) | Gastric cancer | 76 | pEZX-AM03 |
Inquire |
| MIC-AF009-AM03 | MIC-HCH-AM03 | Human | Cancer | Human hepatocellular carcinoma miRNA inhibitor Clone set (Lentiviral) | Hepatocellular Carcinoma | 170 | pEZX-AM03 |
Inquire |
| MIC-AF010-AM03 | MIC-HCI-AM03 | Human | Cancer | Human cholangiocarcinoma miRNA inhibitor Clone set (Lentiviral) | Cholangiocarcinoma | 25 | pEZX-AM03 |
Inquire |
| MIC-AF011-AM03 | MIC-HCJ-AM03 | Human | Cancer | Human thyroid carcinoma miRNA inhibitor Clone set (Lentiviral) | Thyroid Carcinoma | 55 | pEZX-AM03 |
Inquire |
| MIC-AF012-AM03 | MIC-HCK-AM03 | Human | Cancer | Human kidney cancer miRNA inhibitor Clone set (Lentiviral) | Kidney cancer | 67 | pEZX-AM03 |
Inquire |
| MIC-AF013-AM03 | MIC-HCL-AM03 | Human | Cancer | Human lung cancer miRNA inhibitor Clone set (Lentiviral) | Lung cancer | 178 | pEZX-AM03 |
Inquire |
| MIC-AF014-AM03 | MIC-HCM-AM03 | Human | Cancer | Human melanoma miRNA inhibitor Clone set (Lentiviral) | Melanoma | 131 | pEZX-AM03 |
Inquire |
| MIC-AF015-AM03 | MIC-HCN-AM03 | Human | Cancer | Human brain cancer miRNA inhibitor Clone set (Lentiviral) | Brain cancer | 206 | pEZX-AM03 |
Inquire |
| MIC-AF016-AM03 | MIC-HCO-AM03 | Human | Cancer | Human ovarian cancer miRNA inhibitor Clone set (Lentiviral) | Ovarian cancer | 174 | pEZX-AM03 |
Inquire |
| MIC-AF017-AM03 | MIC-HCP-AM03 | Human | Cancer | Human pancreatic cancer miRNA inhibitor Clone set (Lentiviral) | Pancreatic cancer | 166 | pEZX-AM03 |
Inquire |
| MIC-AF018-AM03 | MIC-HCQ-AM03 | Human | Cancer | Human prostate cancer miRNA inhibitor Clone set (Lentiviral) | Prostate cancer | 153 | pEZX-AM03 |
Inquire |
| MIC-AF019-AM03 | MIC-HCR-AM03 | Human | Cancer | Human myeloma miRNA inhibitor Clone set (Lentiviral) | Myeloma | 45 | pEZX-AM03 |
Inquire |
| MIC-AF020-AM03 | MIC-HCS-AM03 | Human | Cancer | Human sarcoma miRNA inhibitor Clone set (Lentiviral) | Sarcoma | 27 | pEZX-AM03 |
Inquire |
| MIC-AF021-AM03 | MIC-HCT-AM03 | Human | Cancer | Human head and neck cancer miRNA inhibitor Clone set (Lentiviral) | Head and Neck cancer | 188 | pEZX-AM03 |
Inquire |
| MIC-AF022-AM03 | MIC-HCU-AM03 | Human | Cancer | Human uterine leiomyoma miRNA inhibitor Clone set (Lentiviral) | Uterine Leiomyoma | 40 | pEZX-AM03 |
Inquire |
| MIC-AF023-AM03 | MIC-HCV-AM03 | Human | Cancer | Human cervical cancer miRNA inhibitor Clone set (Lentiviral) | Cervical cancer | 26 | pEZX-AM03 |
Inquire |
| MIC-AF024-AM03 | MIC-HCW-AM03 | Human | Cancer | Human endometrial cancer miRNA inhibitor Clone set (Lentiviral) | Endometrial cancer | 86 | pEZX-AM03 |
Inquire |
| MIC-AF025-AM03 | MIC-HCX-AM03 | Human | Cancer | Human leukemia miRNA inhibitor Clone set (Lentiviral) | Leukemia | 163 | pEZX-AM03 |
Inquire |
| MIC-AF026-AM03 | MIC-HCY-AM03 | Human | Cancer | Human bladder cancer miRNA inhibitor Clone set (Lentiviral) | Bladder cancer | 63 | pEZX-AM03 |
Inquire |
| MIC-AF027-AM03 | MIC-HCZ-AM03 | Human | Cancer | Human lymphoma miRNA inhibitor Clone set (Lentiviral) | Lymphoma | 112 | pEZX-AM03 |
Inquire |
| MIC-AF028-AM03 NEW! |
Human | Nervous system diseases | Human Alzheimer's disease miRNA inhibitor Clone Set (lentiviral) | Alzheimer's disease | 540 | pEZX-AM03 |
Inquire | |
| MIC-AF029-AM03 NEW! |
Human | Nervous system diseases | Human Parkinson's disease miRNA inhibitor Clone Set (lentiviral) | Parkinson's disease | 271 | pEZX-AM03 |
Inquire | |
| MIC-AF030-AM03 NEW! |
Human | Nervous system diseases | Human Huntington's disease miRNA inhibitor Clone Set (lentiviral) | Huntington's disease | 19 | pEZX-AM03 |
Inquire | |
| MIC-AF031-AM03 NEW! |
Human | Nervous system diseases | Human Cerebral stroke miRNA inhibitor Clone Set (lentiviral) | Cerebral stroke | 370 | pEZX-AM03 |
Inquire | |
| MIC-AF032-AM03 NEW! |
Human | Nervous system diseases | Human Epilepsy miRNA inhibitor Clone Set (lentiviral) | Epilepsy | 110 | pEZX-AM03 |
Inquire | |
| MIC-AF033-AM03 NEW! |
Human | Nervous system diseases | Human Depression miRNA inhibitor Clone Set (lentiviral) | Depression | 131 | pEZX-AM03 |
Inquire | |
| MIC-AF034-AM03 NEW! |
Human | Nervous system diseases | Human Schizophrenia miRNA inhibitor Clone Set (lentiviral) | Schizophrenia | 102 | pEZX-AM03 |
Inquire | |
| MIC-AF035-AM03 NEW! |
Human | Programmed cell death | Human Ferroptosis miRNA inhibitor Clone Set (lentiviral) | Programmed cell death | 39 | pEZX-AM03 |
Inquire | |
| MIC-AF036-AM03 NEW! |
Human | Programmed cell death | Human Autophagy miRNA inhibitor Clone Set (lentiviral) | Programmed cell death | 198 | pEZX-AM03 |
Inquire | |
| MIC-AF037-AM03 NEW! |
Human | Programmed cell death | Human Pyroptosis miRNA inhibitor Clone Set (lentiviral) | Programmed cell death | 36 | pEZX-AM03 |
Inquire | |
| MIC-AF038-AM03 NEW! |
Human | Programmed cell death | Human Apoptosis miRNA inhibitor Clone Set (lentiviral) | Programmed cell death | 62 | pEZX-AM03 |
Inquire | |
| Custom order | Various | Custom-selected | Various | Custom-selected | Inquire |
相关产品
- miArrest™化学合成的miRNA抑制剂
- miTarget™ miRNA 3′ UTR克隆
- miArrest™ miRNA前体表达克隆
- All-in-One™ miRNA引物和qRT-PCR检测试剂盒
- miRNA慢病毒产品
Citations
- Yangyang Zhan, et, al (2026). N6‐Methyladenosine Modification of circIST1 Promotes Hypoxia‐Inducible Factor α–mediated Glycolysis and Progression in Hepatocellular Carcinoma. MedComm DOI: 10.1002/mco2.70577 [miArrest™ miR‐140‐3p and miR‐182 mimics and scrambled control; miArrest™ miR‐140‐3p and miR‐182 inhibitor and scrambled control]
- Yinbiao Cao, et, al (2025). miR-141-3p-loaded extracellular vesicles ameliorate intrahepatic bile duct stone disease by decreasing MUC5AC expression via the MAPK pathway. Intractable Rare Dis Res DOI: 10.5582/irdr.2024.01051 [miArrest™ miRNA inhibitor clone targeting hsa-miR-141-3p; All-in-One™ miRNA qPCR Primers hsa-miR-141-3p, Cat. No. HmiRQP0184,]
- Yinbiao Cao, et, al (2025). miR-141-3p-loaded extracellular vesicles ameliorate intrahepatic bile duct stone disease by decreasing MUC5AC expression via the MAPK pathway. Intractable Rare Dis Res DOI: 10.5582/irdr.2024.01051 [miArrest™ miRNA inhibitor clone targeting hsa-miR-141-3p; All-in-One™ miRNA qPCR Primers hsa-miR-141-3p, Cat. No. HmiRQP0184, HmiRQP9001]
- Johan Guthormsen, et, al (2025). Cardiomyocyte overexpression of microRNA-210 mitigates apoptotic cell death induced by doxorubicin. Cardio-oncology DOI: 10.1186/s40959-025-00429-z [miExpress™ hsa-mir-210 precursor clone, Cat. No. HmiR0167-MR04; miArrest™ miRNA inhibitors against hsa-miR-210-3p, Cat. No. HmiR-AN0317-AM01; miRNA scrambled control clone for pEZX-MR04, Cat. No. CmiR0001-MR04; miRNA inhibitor scrambled control clone for pEZX-AM01, Cat. No. CmiR-AN0001-AM01]
- Patric M Page, et, al (2025). MicroRNA profiling identifies VHL/HIF-2α dependent miR-2355-5p as a key modulator of clear cell Renal cell carcinoma tumor growth. Cancer Cell Int DOI: 10.1186/s12935-025-03711-3 [miArrest™ miRNA inhibitors against miR-145 hsa-mir-2355 and scrambled control, Cat. No. HmiR0909-MR03, CmiR0001-MR03]



